Comparison Between Whole Body DWI and FDG PET/CT in Patients with Simptomatic Multiple Myeloma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

83 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-09-01

Study Completion Date

2027-10-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective is to evaluate the concordance of FDG PET/CT and total body DWI MRI sequences performed during staging and at the completion of therapy. Specifically, we will assess the positivity rates, both patient-based and lesion-based (total and by district), of the two methods during staging and at the completion of therapy. An interim analysis will be conducted comparing the two methods, followed by a final prognostic analysis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Diagnostic Imaging of Myeloma Bone Lesions

NCT03147326

Multiple Myeloma

COMPLETED NA

Comparison Between FDG-PET and MRI for the Assessment of Response to Intensive Chemotherapy in Multiple Myeloma Patients.

NCT00200668

Multiple Myeloma

TERMINATED NA

Magnetic Resonance Imaging of the Whole Body, Including Diffusion, in the Medical Evaluation of Breast Cancers at High Risk for Metastasis and the Follow-up of Metastatic Cancers

NCT02966574

Metastatic Breastcancer

UNKNOWN NA

Evaluation of Whole Body Examination by MRI Integrating the "Zero Time Eco" Sequence (ZTE, Pseudo-CT) for the Detection of Bone Lesions in Multiple Myeloma: Comparison With Pet / CT and Whole Body Scanner

NCT05381077

Multiple Myeloma Bone Metastases

UNKNOWN NA

PET/CT Whole-body Dynamic Acquisition at FDG to Metastatic Melanoma Under Immunotherapy

NCT04272658

Metastatic Melanoma

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Myeloma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients with new diagnosis of symptomatic multiple myeloma

fdg pet/CT and Whole body MRI with DWI

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • Patients with symptomatic myeloma in the staging phase or with suspected symptomatic myeloma in the diagnostic phase

* Patients who have signed the informed consent form

Exclusion Criteria

* Patients simultaneously affected by other neoplastic diseases or with a history of other neoplasms in the previous 5 years

* Age \< 18 years
* Women who are breastfeeding or pregnant
* Patients with metal implants or devices that constitute an absolute contraindication for MRI
* Patients with severe claustrophobia
* Patients with bone pain that prevents prolonged maintenance of the supine position

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No